Hercules Capital, Inc. Share Price
Equities
HTGC
US4270965084
Investment Management & Fund Operators
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.74 USD | +1.02% | +1.70% | +18.42% |
05-17 | UBS Adjusts Price Target on Hercules Capital to $18.50 From $18, Maintains Neutral Rating | MT |
05-15 | Adaptimmune Therapeutics Enters Into $125 Million Term Loan Facility With Hercules Capital | MT |
Sales 2024 * | 509M 39.98B | Sales 2025 * | 553M 43.38B | Capitalization | 3.16B 248B |
---|---|---|---|---|---|
Net income 2024 * | 341M 26.76B | Net income 2025 * | 345M 27.07B | EV / Sales 2024 * | 6.2 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.71 x |
P/E ratio 2024 * |
9.35
x | P/E ratio 2025 * |
9.7
x | Employees | - |
Yield 2024 * |
8.11% | Yield 2025 * |
8.38% | Free-Float | 98.08% |
Latest transcript on Hercules Capital, Inc.
1 day | +1.02% | ||
1 week | +1.70% | ||
1 month | +2.28% | ||
3 months | +9.42% | ||
6 months | +28.18% | ||
Current year | +18.42% |
Managers | Title | Age | Since |
---|---|---|---|
Scott Bluestein
CEO | Chief Executive Officer | 45 | 16/11/10 |
Seth H. Meyer
DFI | Director of Finance/CFO | 55 | 03/03/19 |
Kiersten Botelho
CMP | Compliance Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Gayle Crowell
BRD | Director/Board Member | 73 | 03/02/19 |
Robert Badavas
CHM | Chairman | 71 | 28/02/06 |
Director/Board Member | 61 | 25/09/23 |
Date | Price | Change | Volume |
---|---|---|---|
31/05/24 | 19.74 | +1.02% | 819,484 |
30/05/24 | 19.54 | +0.93% | 593,346 |
29/05/24 | 19.36 | -0.26% | 640,841 |
28/05/24 | 19.41 | -.--% | 764,233 |
Delayed Quote Nyse, May 31, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.42% | 3.16B | |
+12.82% | 1.77B | |
+13.91% | 1.59B | |
-11.54% | 1.21B | |
+19.42% | 793M | |
+10.61% | 674M | |
+30.96% | 561M | |
-4.17% | 506M | |
+34.78% | 489M | |
+70.93% | 316M |
- Stock Market
- Equities
- HTGC Stock